Actively Recruiting
Study of Universal Allogeneic Anti-CD19BCMA CAR T-Cell Therapy for Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients Aged 10 and Older
Led by The Second Hospital of Anhui Medical University · Updated on 2026-04-15
15
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of a new universal allogeneic anti-CD19BCMA CAR T-cell therapy for patients with autoimmune hemolytic anemia AIHA who have not responded to three or more previous treatments. This early phase 1 trial focuses on individuals with relapsed or refractory AIHA, including warm antibody type, cold agglutinin disease, mixed type, and other forms, aiming to provide an alternative option for difficult-to-treat cases. The treatment involves a single intravenous infusion of the universal allogeneic CAR T-cells following a lymphodepleting chemotherapy regimen with fludarabine and cyclophosphamide. The study includes an initial treatment period with detailed monitoring and an interim analysis 12 weeks after the infusion to evaluate safety and clinical response. The intervention being tested is a biological therapy called QT-219C Cell Injection. Participants will undergo various assessments including blood tests to measure CAR T-cell levels and monitor organ function, as well as evaluations for adverse events and clinical response up to 24 weeks after treatment. Safety monitoring will continue for up to 12 months post-infusion. The study requires signing informed consent, compliance with contraception requirements for those of childbearing potential, and regular follow-up visits. The total participation duration varies according to individual response and safety monitoring needs.
CONDITIONS
Brief Title
UCAR T-cell Therapy Targeting CD19/BCMA in Relapsed/Refractory Autoimmune Hemolytic Anemia
Research Team
Z
Zhimin Zhai, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here